Oklahoma City, OKNCT06136884Now EnrollingIRB Ready

Solid Tumor Malignancies Clinical Trial in Oklahoma City, OK

Access cutting-edge solid tumor malignancies treatment through this clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.

Sponsored by A2A Pharmaceuticals Inc.

Quick Self-Assessment

See if you qualify for this Oklahoma City location

Preparing your pre-screening questions…

Expert Care in Oklahoma City

Access solid tumor malignancies specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumor malignancies treatment provided free

Apply for This Oklahoma City Location

Check if you qualify for this solid tumor malignancies clinical trial in Oklahoma City, OK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Oklahoma City

    Convenient for OK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Oklahoma City site if eligible
  4. 4Begin participation

About This Solid Tumor Malignancies Study in Oklahoma City

The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.

Sponsor: A2A Pharmaceuticals Inc.

Who Can Participate

Inclusion Criteria

Adults ≥ 18 years of age.
Patient has histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors with TP53 mutation/loss and with/without brain metastasis. Patients must have relapsed/be refractory to at least 1 line of systemic therapy in the metastatic setting (excluding melanoma).
Prostate cancer:
mCRPC with histologic confirmation of adenocarcinoma. mCRPC with neuroendocrine features or mixed histology are excluded
Patients will be enrolled irrespective of the TP53 status
Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL
Is surgically or medically castrated, with testosterone levels of less than 50 ng/dL
Patients who progressed on at least 1 prior novel androgen receptor AR-targeted therapy (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), and or at least 1 prior systemic chemotherapy (e.g., docetaxel)
Solid tumors with brain metastasis:
Histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors excluding melanoma with TP53 mutation/loss and tumor must have relapsed/be refractory to at least 1 line of systemic therapy. Untreated brain metastases not requiring immediate local CNS therapy
Previously treated brain metastases with progression of previous lesions or new lesions, but not requiring immediate local CNS therapy
At least one measurable untreated brain lesion ≥0.5 cm and \<3.0 cm in the longest axis
Prior SRS radiosurgery (must be completed within 7 days of study treatment initiation) is allowed as long as the previous treatment volume does not overlap with the current targets.
Measurable disease per RECIST v1.1 criteria. For mCRPC patients, tumor response will be evaluated using RECIST version 1.1 (soft tissue) and PCWG-3 criteria (bone) and efficacy endpoints will also include radiographic progression-free survival (rPFS), PSA50 response and PSA progression
Adequate bone marrow reserve, cardiac, liver, and renal function:
Absolute neutrophil count (ANC) ≥ 1,500/mm3
Platelet count ≥ 100,000/mm3
Hemoglobin ≥ 9 g/dL
Bilirubin ≤ 1.5 × upper limit of normal (ULN) or direct bilirubin ≤ ULN for patients with total bilirubin levels \>1.5 × ULN
Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present)
INR ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants
Creatinine clearance ≥ 60 mL/min (by Cockroft Gault formula).
Female patients of child-bearing potential must have a negative serum pregnancy test and use at least 1 form of acceptable birth control method listed below as approved by the Investigator before initiating study treatment and for 3 months after the last dose of study drug.
Sterilization
Any hormonal contraceptives (non-CYP 3A4 inhibitors) associated with inhibition of ovulation
IUD (intrauterine device) or intrauterine hormone releasing system
Male patients must be sterilized or use a form of barrier contraception, such as condoms with spermicide, during the study and for 3 months after the last dose of study drug.
Life expectancy of ≥ 3 months.
Ability to provide written informed consent.
An Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.

Exclusion Criteria

Patients with symptomatic brain metastases requiring treatment and/or leptomeningeal disease
Patients with a previous history of another malignancy (other than cured basal cell or squamous cell carcinoma of the skin or cured in-situ carcinoma) within 3 years of study entry.
Patients with uncontrolled pleural effusions, pericardial effusion, or ascites that do not resolve.
Patients with gastrointestinal tract disease causing the inability to take oral medication (e.g., swallowing difficulties, malabsorption syndromes, extensive small bowel resection \[\> 100cm\], gastric bypass surgery).
Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception.
Known human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (excluding cured HBV and/or cured HCV infection).
Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the Investigator (e.g., uncontrolled congestive heart failure, active infection).
Radiation therapy to \> 30% of bone marrow within 3 months before study entry.
Patients with clinically significant autoimmune disease, either currently present of present within 2 years, including a current requirement for systemic immunosuppressive therapy equivalent to \> 10 mg/prednisone daily (local immunosuppressive therapy such as inhaled or topical corticosteroids is allowed). 11\. Patients with abnormal or clinically significant electrocardiogram (ECG) abnormality, including but not limited to a confirmed corrected QT interval using Fridericia's formula (QTcF) \> 470 msec. 12\. Patient has received systemic anticancer therapy within 3 weeks or 5 half-lives, whichever is shorter. 13\. Patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline. 14\. Any of the following conditions (on-study testing is not required): a. Known HIV-infected patients unless on effective anti-retroviral therapy with an undetectable viral load within 6 months and no opportunistic infection within the past 12 months, or b. Known or suspected hepatitis B if active infection (patients with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or c. Known or suspected hepatitis C infection that has not been treated and cured unless currently on treatment with an undetectable viral load. 15\. Administration of strong or moderate cytochrome (CYP) 3A4 inhibitors and inducers within 14 days or 5 half-lives (whichever is shorter) prior to the administration of study drug.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Oklahoma City?

Yes, this clinical trial (NCT06136884) has an active research site in Oklahoma City, OK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor Malignancies Treatment Options in Oklahoma City, OK

If you're searching for solid tumor malignancies treatment options in Oklahoma City, OK, this clinical trial (NCT06136884) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Oklahoma City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumor malignancies specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor malignancies clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Oklahoma City, OK

See all advanced solid tumors clinical trials recruiting in Oklahoma City — not just this study.

Browse Advanced Solid Tumors Trials in Oklahoma City →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Oklahoma City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Oklahoma City, OK